Skip to main content
All lobbying filings

SANOFI US SERVICES INC.

Lobbying for SANOFI US SERVICES INC

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $2,580,000.00 expenses · posted Apr 20, 2026

Official filing document

 Bills named in this filing 17
  • HR 7174
    Full Cost of War Act
  • S 832
    EPIC Act of 2025
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 6423
    HELP Copays Act
  • HR 2880
    To provide employment protections for, and reinstatement of, certain probationary Federal career employees, and for oth…
  • HR 5376
    Impacts and Outcomes for Health Career Training Act
  • HR 5539
    POW Priority Care Act of 2025
  • HR 7834
    Safe Cloud Storage Act
  • S 864
    HELP Copays Act
  • S 1339
    Stop CCP Money Laundering Act of 2025
  • S 1375
    SNOOP Act of 2025
  • S 1542
    Uyghur Policy Act of 2025
  • S 2027
    Prescription Information Modernization Act of 2025
  • S 4504
    Full-Service Community School Expansion Act of 2026
  • HR 8698
    Lower Prices at the Pump Act
  • S 43
    Skinny Labels, Big Savings Act
  • S 2276
    ETHIC Act
 Lobbying activity 6
Health Issues

340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient Experience/Patient Focused Drug Development within the FDA/AG Appropriations; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues.

Medicare/Medicaid

340B; Medicare Negotiation, and Most Favored Nation.

Trade (domestic/foreign)

Supply Chain Issues; and Importation issues.

Taxation/Internal Revenue Code

Supply Chain issues; TRIP Waivers; and Vaccine Injury Compensation Program.

Copyright/Patent/Trademark

S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property.

Manufacturing

Insulin; Pharmacy Benefits Managers (PBMs); Taxes- General Issues; Type 1 Diabetes Screening; and Vaccines - General Issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem